Pre-clinical study with Lanifibranor – Prof Gracia-Sancho
Prof Gracia-Sancho, Spain, discusses his oral presentation at the Liver meeting 2019 in Boston and the reasons why PPAR agonists could be a very valuable therapeutic option for the treatment of advanced chronic liver disease.
Read MorePre-clinical study with Lanifibranor – Prof Gracia-SanchoProf Jordi Gracia-Sancho, Barcelona, discusses the need to develop new therapeutic approaches that target more than one molecular pathway for chronic liver disease.
For me, one of the key take home messages of…
Prof Jordi Gracia-Sancho, Barcelona, discusses this important topic in an interview filmed in Boston during the Liver meeting 2019.
Prof Jordi Gracia-Sancho, Barcelona, discusses this important topic in an interview filmed in Boston during the Liver meeting 2019.
Read MoreProf Jordi Gracia-Sancho, Barcelona, discusses this important topic in an interview filmed in Boston during the Liver meeting 2019.